Lieber Jonathan I
SEC-identified person · CIK 1350090 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Rallybio Corp RLYB | See Remarks | filed 2023–2026 |
| Salarius Pharmaceuticals, Inc. SLRX | Director | filed 2020–2024 |
| Applied Genetic Technologies Corp AGTC | Chief Financial Officer | filed 2021–2022 |
| Checkmate Pharmaceuticals, Inc. CMPI | See Remarks | filed 2020–2020 |
| Ocugen, Inc. OCGN | Chief Financial Officer | filed 2015–2018 |
| Repligen Corp RPGN | CFO | filed 2012–2013 |
| Altus Pharmaceuticals Inc. ALTU | VP, CFO and Treasurer | filed 2006–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.